This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (28)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in JAMA  Topic Collections  • Cardiovascular System  • Quality of Care  • Evidence-Based Medicine  • Arrhythmias  • Drug Therapy, Other  • Congestive Heart Failure/ Cardiomyopathy  • Alert me on articles by topic  Social Bookmarking   What's this?

An Evidence-Based Review of Clinical Indications

Patricia Vassallo, MD; Richard G. Trohman, MD

JAMA. 2007;298:1312-1322.

Context  Although amiodarone is approved by the US Food and Drug Administration only for refractory ventricular arrhythmias, it is one of the most frequently prescribed antiarrhythmic medications in the United States.

Objective  To evaluate and synthesize evidence regarding optimal use of amiodarone for various arrhythmias.

Evidence Acquisition  Systematic search of MEDLINE to identify peer-reviewed clinical trials, randomized controlled trials, meta-analyses, and other studies with clinical pertinence. The search was limited to human-participant, English-language reports published between 1970 and 2007. Amiodarone was searched using the terms adverse effects, atrial fibrillation, atrial flutter, congestive heart failure, electrical storm, hypertrophic cardiomyopathy, implantable cardioverter-defibrillator, surgery, ventricular arrhythmia, ventricular fibrillation, and Wolff-Parkinson-White. Bibliographies of identified articles and guidelines from official societies were reviewed for additional references. Ninety-two identified studies met inclusion criteria and were included in the review.

Evidence Synthesis  Amiodarone may have clinical value in patients with left ventricular dysfunction and heart failure as first-line treatment for atrial fibrillation, though other agents are available. Amiodarone is useful in acute management of sustained ventricular tachyarrythmias, regardless of hemodynamic stability. The only role for prophylactic amiodarone is in the perioperative period of cardiac surgery. Amiodarone may be effective as an adjunct to implantable cardioverter-defibrillator therapy to reduce number of shocks. However, amiodarone has a number of serious adverse effects, including corneal microdeposits (>90%), optic neuropathy/neuritis (1%-2%), blue-gray skin discoloration (4%-9%), photosensitivity (25%-75%), hypothyroidism (6%), hyperthyroidism (0.9%-2%), pulmonary toxicity (1%-17%), peripheral neuropathy (0.3% annually), and hepatotoxicity (elevated enzyme levels, 15%-30%; hepatitis and cirrhosis, <3% [0.6% annually]).

Conclusion  Amiodarone should be used with close follow-up in patients who are likely to derive the most benefit, namely those with atrial fibrillation and left ventricular dysfunction, those with acute sustained ventricular arrhythmias, those about to undergo cardiac surgery, and those with implantable cardioverter-defibrillators and symptomatic shocks.

Author Affiliations: Department of Medicine, Section of Cardiology, Electrophysiology, Arrhythmia, and Pacemaker Service, Rush University Medical Center, Chicago, Illinois.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Use of Amiodarone
John R. Kapoor
JAMA. 2007;298(22):2617.
EXTRACT | FULL TEXT  

Use of Amiodarone
Michele Coceani
JAMA. 2007;298(22):2617-2618.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Frequency, Characteristics, and Risk Factors for Amiodarone Neurotoxicity
Orr and Ahlskog
Arch Neurol 2009;66:865-869.
ABSTRACT | FULL TEXT  

Histological patterns in drug-induced liver disease
Ramachandran and Kakar
J. Clin. Pathol. 2009;62:481-492.
ABSTRACT | FULL TEXT  

Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials
Piccini et al.
Eur Heart J 2009;30:1245-1253.
ABSTRACT | FULL TEXT  

Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications
Schmitt et al.
Eur Heart J 2009;30:1038-1045.
ABSTRACT | FULL TEXT  

Antifibrillatory Agents and Potassium Channels in the Atria: Pore Block versus Channel Trafficking
McEwen and Martens
Mol. Interv. 2009;9:79-86.
ABSTRACT | FULL TEXT  

Amiodarone-induced neurotoxicity
Willis and Lugo
Am J Health Syst Pharm 2009;66:567-569.
ABSTRACT | FULL TEXT  

Continuous vs Episodic Prophylactic Treatment With Amiodarone for the Prevention of Atrial Fibrillation: A Randomized Trial
Ahmed et al.
JAMA 2008;300:1784-1792.
ABSTRACT | FULL TEXT  

Amiodarone Use in Patients with Documented Hypersensitivity to Intravenous Contrast Dye
Snider et al.
The Annals of Pharmacotherapy 2008;42:1349-1350.
FULL TEXT  

Symptomatic heart failure is the most important clinical correlate of impaired quality of life, anxiety, and depression in implantable cardioverter-defibrillator patients: a single-centre, cross-sectional study in 610 patients
Johansen et al.
Europace 2008;10:545-551.
ABSTRACT | FULL TEXT  

Synergistic activity of azoles with amiodarone against clinically resistant Candida albicans tested by chequerboard and time-kill methods
Guo et al.
J Med Microbiol 2008;57:457-462.
ABSTRACT | FULL TEXT  

Use of Amiodarone
Kapoor
JAMA 2007;298:2617-2617.
FULL TEXT  

Use of Amiodarone
Coceani
JAMA 2007;298:2617-2618.
FULL TEXT